Media Invitation to Attend the SITC 26th Annual Meeting & Associated Programs: Deliver Breaking News on the Latest Advances in Cancer Immunotherapy.

Share Article

This is a media invitation to attend the SITC 26th Annual Meeting & Associated Programs

Join the world's leading researchers in cancer immunotherapy at the SITC 26th Annual Meeting & Associated Programs, November 1-6, 2011 in North Bethesda, MD. Hear first-hand the latest and most newsworthy cancer research straight from the experts.

Members of the media can register free of charge for a press pass, granting access to exciting educational programs that explore the latest advances in cancer therapy, including:

Summit on Cell Therapy for Cancer – November 1-2, 2011

  •     An exciting mix of perspectives, concepts and techniques related to cellular therapy that are not normally presented together at a single meeting, from research on induced pluripotent stem cells to specific modalities and assessment of cell therapies for cancer

Primer on Tumor Immunology and Cancer Immunotherapy – November 3, 2011

  •     A general overview of the principles of tumor immunology and immune-based cancer treatments, promoting appropriate clinical application of cancer immunotherapies to improve patient outcomes
  •     Dynamic lectures covering the biology of immune cells, cellular processes and the tumor microenvironment

Workshop on Immunotherapy Combinations – November 3, 2011

  •     Presentations and panel discussions on strategies and current clinical trials combining immunotherapy with other treatments, including other immunotherapies, new targeted therapeutics, and conventional cancer therapies
  •     A Keynote Address on “The CITN Perspective on Immunotherapy Combinations” by Martin A. "Mac" Cheever, MD, Principal Investigator, Cancer Immunotherapy Trials Network (CITN)

26th Annual Meeting - November 4-6, 2011

  •     Presentations from leaders in the field on cutting-edge results and methodologies, with topics ranging from biology and application of dendritic cells to high throughput technologies for immune monitoring
  •     Updates on important initiatives in the field of cancer immunotherapy, by key representatives from the NIH, NCI, FDA, and the CITN

Hot Topic Symposium: Targeting the Next Generation of Inhibitory Pathways – November 6, 2011

  •     The newest approaches to targeting immune inhibitory pathways in cancer
  •     Cutting-edge research on cellular and molecular attributes of inhibitory pathways associated with CTLA-4, B7x, Tim-3, VISTA, and IDO

Founded in 1984, the Society for Immunotherapy of Cancer (formerly the International Society for Biological Therapy of Cancer; iSBTc) is a non-profit organization of clinicians, researchers, students, post-doctoral fellows, and allied health professionals dedicated to improving cancer patient outcomes by advancing the development and application of cancer immunotherapy through interaction, innovation and leadership. For more information about SITC, please visit the Society website at http://www.sitcancer.org.

For more information or to register for the SITC 26th Annual Meeting & Associated Programs, contact Jennifer Warren at (414) 271-2456 or jwarren@sitcancer.org

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website